Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).
How pharmacy benefit managers influence drug pricing
This is Part 2 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. The point of prescription
June 12, 2024